Pharmacological inhibition of the ataxia telangiectasia and Rad3-similar protein serine/threonine kinase (ATR; also known as FRAP-similar protein (FRP1)) has emerged being a promising strategy for cancer treatment that exploits synthetic lethal interactions with proteins linked to DNA hurt fix, overcomes resistance to other therapies and boosts antitumour immunity. Several novel, https://shaneuzejm.designertoblog.com/58090668/not-known-factual-statements-about-molnupiravir